A. Mwakingwe-Omari

No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a COVID-19 mRNA-1273 booster vaccine in adults aged 50 years and older: A randomized trial

T. Breuer, B. Leav, J. Danier, 2023, medRxiv.

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Hyo Youl Kim, Kenjiro Nakamura, A. Schaefer, 2022, Open forum infectious diseases.

Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity

S. Hoffman, S. Bhatia, J. Duan, 2021, Nature.

The Adjuvanted Recombinant Zoster Vaccine Co-Administered with the 13-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥50 Years: a Randomized Trial.

Jyoti Soni, J. Min, Megan E Riley, 2021, The Journal of infection.

No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial

T. Breuer, B. Leav, J. Danier, 2023, Clinical Infectious Diseases.

No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial

B. Leav, J. Danier, P. Pirrotta, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.